Insight 14

When supplements have a place in hair care

Last reviewed

Published

People can take a supplement for very different reasons. One needs help correcting a nutritional shortfall. Another is trying a formulation studied for hair growth. A third is addressing a condition contributing to hair loss.

The recommendation should explain the purpose, evidence and way to judge benefit. The word supplement alone tells us little about any of those points.

Start with the intended use

Iron, vitamin B12, vitamin D, zinc and other nutrients can enter a plan when the history and assessment support a need. Food intake, absorption, blood loss and existing supplementation all matter. Excess intake can also create problems.1

A normal blood result cannot describe every aspect of nutrition. Standard tests are unavailable or imperfect for some ingredients and proposed effects. That calls for a considered assessment of the need and evidence.

Other ingredients are studied for particular conditions. NAC, or N-acetylcysteine, has been tested for hair-pulling disorder. An adult trial found benefit, while a pediatric trial did not find benefit over placebo. The condition and population are essential to interpreting that evidence.2,3

Give biotin a complete explanation

Biotin is an essential vitamin, and deficiency is very rare. Evidence for routine biotin alone to improve hair in people without deficiency is limited. Very rarely, an inherited condition makes it difficult for the body to use biotin. These conditions are often identified through newborn screening or symptoms in infancy. Biotin deficiency can also cause brittle nails.4,5

Our patent describes laboratory experiments in which different amounts of biotin increased or reduced hair stem cell numbers. In these experiments, biotin alone did not activate Wnt/beta-catenin. When the cells were stimulated to activate, biotin substantially reduced the Wnt/beta-catenin growth signal, which is required for hair growth.6

Biotin can also interfere with some laboratory tests. Tell the clinician and laboratory the product and dose before testing so they can give appropriate instructions.4,7

The purpose of the supplement determines which evidence matters.

Assess the preparation that was studied

Named preparations help make evidence specific. Our network meta-analysis compared trial results for ALRV5XR, Nutrafol and Viviscal under defined eligibility criteria. These results concern the formulations, populations and study periods included.8

The ALRV5XR clinical trials evaluated oral capsules with topical products. Their result describes that regimen and does not isolate the capsule's contribution.9

An ingredient study cannot establish the effect of every mixture containing it. A current label also needs comparison with the studied preparation when formulations change.

Make continued use a decision

Bring every product label, dose and reason for taking it. Review overlapping ingredients, other treatments, tolerance and cost. The plan should define the intended benefit and when it will be reassessed.

Limited evidence leaves uncertainty that should be explained. A person's experience deserves attention, alongside the possibility of natural recovery, another treatment effect or a changing condition. That gives continued use a clear basis for review.

Author disclosure

Peter R. Feldman is an inventor of ALRV5XR and of the patent in reference 6, and a coauthor of references 8 and 9. Patent-reported laboratory findings and clinical outcomes are identified separately.

References

  1. Guo EL, Katta R. Diet and hair loss: Effects of nutrient deficiency and supplement use. Dermatol Pract Concept. 2017;7:1-10. doi:10.5826/dpc.0701a01. Return to text ↑
  2. Grant JE, Odlaug BL, Kim SW. N-Acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: A double-blind, placebo-controlled study. Arch Gen Psychiatry. 2009;66:756-763. doi:10.1001/archgenpsychiatry.2009.60. Return to text ↑
  3. Bloch MH, Panza KE, Grant JE, Pittenger C, Leckman JF. N-Acetylcysteine in the treatment of pediatric trichotillomania: A randomized, double-blind, placebo-controlled add-on trial. J Am Acad Child Adolesc Psychiatry. 2013;52:231-240. doi:10.1016/j.jaac.2012.12.020. Return to text ↑
  4. National Institutes of Health Office of Dietary Supplements. Biotin Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/Biotin-HealthProfessional/ Return to text ↑
  5. Newborn Screening Ontario. Biotinidase Deficiency. https://www.newbornscreening.on.ca/en/results/screen-positive-results/disease-information/biotinidase-deficiency/ Return to text ↑
  6. Feldman PR, Marra LE, Brown DM, Cahan DJ. Botanicals as WNT/beta-catenin activators, molecular pathway regulators, tissue regenerators and health biomarker regulators. US patent 12708655 B2. Issued August 18, 2026. Laboratory experiments and Figure 2. https://patents.google.com/patent/US12708655B2/en Return to text ↑
  7. US Food and Drug Administration. Biotin Interference with Troponin Lab Tests. https://www.fda.gov/medical-devices/in-vitro-diagnostics/biotin-interference-troponin-lab-tests-assays-subject-biotin-interference Return to text ↑
  8. Feldman PR, Gentile P, Piwko C, et al. Hair regrowth treatment efficacy and resistance in androgenetic alopecia. Front Med. 2023;9:998623. doi:10.3389/fmed.2022.998623. Return to text ↑
  9. Feldman PR, Fiebig KM, Piwko C, et al. Safety and efficacy of ALRV5XR in women with androgenetic alopecia or telogen effluvium: A randomized, double-blinded, placebo-controlled clinical trial. EClinicalMedicine. 2021;37:100978. doi:10.1016/j.eclinm.2021.100978. Return to text ↑

Medical disclaimer: FHI Insights is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Consult a licensed healthcare professional regarding individual health concerns or treatment decisions.